Proglucagon-derived peptides: mechanisms of action and therapeutic potential

Physiology (Bethesda). 2005 Oct;20:357-65. doi: 10.1152/physiol.00030.2005.

Abstract

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy
  • Dipeptidyl Peptidase 4 / drug effects
  • Disease
  • Glucagon / analogs & derivatives*
  • Glucagon / physiology
  • Glucagon / therapeutic use
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptide 2
  • Glucagon-Like Peptide-1 Receptor
  • Glucagon-Like Peptides / physiology
  • Humans
  • Intestinal Diseases / drug therapy
  • Peptide Fragments / physiology
  • Peptide Fragments / therapeutic use
  • Peptides / metabolism
  • Peptides / physiology*
  • Peptides / therapeutic use*
  • Proglucagon
  • Protease Inhibitors / therapeutic use
  • Protein Precursors* / physiology
  • Protein Precursors* / therapeutic use
  • Receptors, Glucagon / agonists
  • Receptors, Glucagon / physiology

Substances

  • GLP1R protein, human
  • Glucagon-Like Peptide 2
  • Glucagon-Like Peptide-1 Receptor
  • Peptide Fragments
  • Peptides
  • Protease Inhibitors
  • Protein Precursors
  • Receptors, Glucagon
  • Proglucagon
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide 1
  • Glucagon
  • Dipeptidyl Peptidase 4